Ticagrelor with or without Aspirin in High-Risk Patients after PCI
Source: View publication →
In high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy without incident, dropping aspirin and continuing ticagrelor monotherapy significantly reduced clinically relevant bleeding without increasing the risk of death, myocardial infarction, or stroke.
Key Findings
Study Design
Study Limitations
Clinical Significance
The TWILIGHT trial established a new standard of care for antithrombotic de-escalation following PCI. By demonstrating that withdrawing aspirin after 3 months of DAPT and continuing ticagrelor monotherapy halves the risk of major bleeding without compromising anti-ischemic efficacy, the trial supports tailored, aspirin-free strategies in high-risk patients to optimize the balance of bleeding and thrombosis.
Historical Context
Historically, standard practice following PCI mandated 6 to 12 months of dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) to mitigate the risk of stent thrombosis. However, prolonged DAPT drives up bleeding events, which are strongly associated with increased morbidity and mortality. In the era of newer-generation drug-eluting stents (which carry a substantially lower intrinsic risk of thrombosis), the TWILIGHT trial was designed to test whether the bleeding risk of aspirin could be safely eliminated early (at 3 months) by relying on the potent P2Y12 inhibition of ticagrelor alone.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of ticagrelor differ from that of aspirin, and why might ticagrelor monotherapy provide sufficient platelet inhibition to prevent stent thrombosis without concurrent cyclooxygenase inhibition?
Key Response
Aspirin irreversibly inhibits COX-1, preventing thromboxane A2 generation, while ticagrelor reversibly and directly blocks the P2Y12 ADP receptor. P2Y12 plays a central role in amplifying platelet activation. Potent blockade of P2Y12 by ticagrelor is often sufficient to prevent stent thrombosis, rendering the addition of aspirin redundant for efficacy but additive for bleeding risk, particularly gastrointestinal bleeding due to systemic COX-1 inhibition.
When managing a patient after PCI, what clinical or angiographic features defined the 'high-risk' population in the TWILIGHT trial, and how would you practically implement this strategy at a 3-month follow-up visit?
Key Response
TWILIGHT defined high risk via clinical criteria (e.g., age over 65, female sex, troponin-positive ACS, diabetes, CKD) or angiographic criteria (e.g., multivessel CAD, target lesion requiring over 30mm stent, bifurcation, left main). Practically, if a patient matching these criteria presents at 3 months post-PCI with no bleeding or ischemic events, the resident should discontinue aspirin and continue ticagrelor 90 mg twice daily.
The TWILIGHT trial included patients with NSTEMI and unstable angina but explicitly excluded those presenting with STEMI. As a cardiology fellow, how do you weigh the ischemic risk of dropping aspirin at 3 months in a STEMI patient who underwent complex PCI compared to an NSTEMI patient?
Key Response
STEMI patients generally have a higher early prothrombotic burden and were excluded from TWILIGHT, making direct extrapolation challenging. Fellows must recognize that while TWILIGHT established the safety of dropping aspirin in NSTEMI/stable CAD, applying this to STEMI requires individualized risk assessment, although subsequent trials like TICO have provided more specific evidence supporting P2Y12 monotherapy after 3 months even in STEMI populations.
Historically, the standard was to prolong dual antiplatelet therapy in high-ischemic-risk patients, as seen in the DAPT trial. How do you reconcile the TWILIGHT results with the DAPT study, and how does this shift your shared decision-making discussions?
Key Response
The DAPT trial showed extending DAPT reduced ischemia but increased bleeding, primarily using clopidogrel. TWILIGHT utilizes a more potent P2Y12 inhibitor (ticagrelor), which maintains a high ceiling of ischemic protection on its own. This represents a paradigm shift from 'more is better' to 'less is more' regarding aspirin, teaching us that modifying the antiplatelet regimen based on the potency of the P2Y12 inhibitor can successfully mitigate bleeding without sacrificing ischemic safety.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TWILIGHT trial utilized a 3-month open-label run-in period before randomization. How does this 'event-free survivor' enrichment strategy impact the internal validity of the study and the statistical power required for the non-inferiority margin of ischemic outcomes?
Key Response
A run-in period depletes the cohort of patients who experience early bleeding or ischemic events, which are most frequent in the first 30 to 90 days. While this maximizes the safety profile of the intervention phase, it lowers the overall event rate. A lower event rate can artificially make non-inferiority easier to achieve if the absolute margin is fixed, and it limits generalizability strictly to patients who have already proven they can tolerate 3 months of DAPT.
The TWILIGHT study was primarily powered for superior bleeding outcomes and secondarily for non-inferiority in ischemic events with a non-inferiority margin hazard ratio of 1.6. As an editor, what concerns might you raise regarding this wide margin for the composite ischemic endpoint?
Key Response
A non-inferiority margin of 1.6 means the trial accepted up to a 60 percent relative increase in ischemic events as 'non-inferior.' Although the observed hazard ratio was 0.99, a rigorous peer reviewer would flag that the trial was not sufficiently powered to definitively rule out small but clinically catastrophic increases in stent thrombosis or myocardial infarction, particularly in underrepresented subgroups.
Based on the TWILIGHT trial and similar contemporary data, how should ACC/AHA and ESC guidelines be updated regarding the duration of aspirin therapy post-PCI in high-risk patients, and what Class of Recommendation should be assigned?
Key Response
The TWILIGHT trial directly influenced the 2021 ACC/AHA and 2020 ESC guidelines. Based on this evidence, dropping aspirin after 1 to 3 months of DAPT and continuing a P2Y12 inhibitor (like ticagrelor) in patients who are event-free and not at high bleeding risk is now given a Class IIa recommendation (Level of Evidence A). This updates older guidelines that rigidly recommended 12 months of DAPT for all ACS patients, shifting toward individualized bleeding reduction strategies.
Clinical Landscape
Noteworthy Related Trials
GLOBAL LEADERS
Tested
1 month DAPT followed by 23 months ticagrelor monotherapy
Population
Patients undergoing PCI with a biolimus A9-eluting stent
Comparator
12 months standard DAPT followed by 12 months aspirin
Endpoint
All-cause mortality or non-fatal new Q-wave MI at 2 years
STOPDAPT-2
Tested
1 month DAPT followed by clopidogrel monotherapy
Population
Patients undergoing PCI
Comparator
12 months standard DAPT
Endpoint
Composite of cardiovascular death, MI, ischemic stroke, stent thrombosis, or TIMI major/minor bleeding at 12 months
TICO
Tested
3 months DAPT followed by ticagrelor monotherapy
Population
Patients with acute coronary syndromes undergoing PCI
Comparator
12 months ticagrelor-based DAPT
Endpoint
Net adverse clinical events (TIMI major bleeding and MACE) at 12 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis